More than a third of patients on Wegovy pill are new to GLP-1 drugs - report
Early data shows that 36% of patients using Novo Nordisk’s new Wegovy weight-loss pill had never taken a GLP-1 medication before, while others switched from injectable versions like Wegovy or Eli Lilly’s Zepbound. The findings come from a Truveta study of 8,762 U.S. patients following FDA approval in December 2025.
Robin Respaut/Reuters
February 12, 2026
FILE PHOTO: Wegovy pens are sorted at a packaging line at Novo Nordisk's facility in Hillerod, Denmark, March 8, 2024.
Tom Little/Reuters
Among early users of Novo Nordisk's NOVOb.COnew Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Of patients who started a new pill prescription, 21.1% had previously taken the injectable version of Wegovy and 15.8% switched from Eli Lilly's LLY.N Zepbound, another injectable GLP-1 medicine, according to Truveta data.
Truveta reviewed health records from 8,762 patients with evidence of a prescription for the new Wegovy pill, which was approved by the U.S. Food and Drug Administration on December 22.
-Robin Respaut/Reuters
TOP HEALTH STORIES
WHO chief to meet Congo president, as aid group warns Ebola likely spread undetected for months
Ebola recoveries bring signs of hope in DRC as suspected cases emerge outside Africa
Prostate cancer drug reduces risk of cancer spread and death in late-stage study
LATEST NEWS
53 rescuers work together to save man stuck in deep Italian cave
Israel's Netanyahu orders attacks in Beirut's southern suburbs
Five dead, two injured in fire at Hanwha Aerospace plant in South Korea
GET IN TOUCH
desk@myparaluman.ph
Tektite Towers (East), Exchange Road
Ortigas Center. San Antonio 1600
City of Pasig, NCR, Philippines
+63284298877
MENU
© 2026 Paraluman News Publication